GW touts pos­i­tive sur­vival ben­e­fit in small brain can­cer study; Abl­ynx files for ul­tra-rare dis­ease drug OK

• GW Phar­ma is tout­ing claims that a com­bi­na­tion of tetrahy­dro­cannabi­nol (THC) and cannabid­i­ol (CBD) pro­duced pos­i­tive sur­vival ben­e­fits in a small study of 21 pa­tients with re­cur­rent glioblas­toma mul­ti­forme, a com­mon form of brain can­cer. The drug arm had an 83 per­cent one year sur­vival rate com­pared with 53 per­cent for pa­tients in the place­bo group. Draw­ing a di­rect link be­tween the drug and sur­vival in such a small group, though, is dif­fi­cult to do. The com­pa­ny is now ex­plor­ing a piv­otal study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.